Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMRX Chimerix	$8.54	$8.54	$0.75 ▼ $8.55	$801.09M	-0.17	2.72 million shs	N/A
DRUG Bright Minds Biosciences	$26.58 +1.8%	$29.45	$0.93 ▼ $79.02	$187.12M	-5.74	822,074 shs	29,409 shs
ETNB 89BIO	$9.73 -0.9%	$8.99	$4.16 ▼ $11.84	$1.42B	1.3	1.51 million shs	1.93 million shs
GPCR Structure Therapeutics	$20.51 -1.1%	$23.38	$13.22 ▼ $47.48	$1.18B	-1.87	837,676 shs	425,852 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMRX Chimerix	0.00%	0.00%	0.00%	+0.47%	+874.89%
DRUG Bright Minds Biosciences	+12.20%	-3.62%	+0.42%	-27.69%	+2,307.34%
ETNB 89BIO	-0.41%	-1.80%	-1.31%	+44.41%	+22.60%
GPCR Structure Therapeutics	-1.61%	-6.15%	-4.51%	+31.35%	-47.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMRX Chimerix	0.6839 of 5 stars	1.0	0.0	4.1	0.6	1.7	0.6
DRUG Bright Minds Biosciences	3.2024 of 5 stars	3.6	3.0	0.0	4.0	2.5	0.0
ETNB 89BIO	2.1135 of 5 stars	3.5	1.0	0.0	3.1	0.8	0.6
GPCR Structure Therapeutics	2.6221 of 5 stars	3.5	3.0	0.0	2.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMRX Chimerix	2.00	Hold	$8.53	-0.08% Downside
DRUG Bright Minds Biosciences	3.25	Buy	$83.25	213.21% Upside
ETNB 89BIO	3.00	Buy	$26.43	171.62% Upside
GPCR Structure Therapeutics	3.00	Buy	$76.17	271.36% Upside

Current Analyst Ratings Breakdown

Latest DRUG, GPCR, ETNB, and CMRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
6/23/2025	GPCR Structure Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$65.00
6/23/2025	GPCR Structure Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$89.00
6/11/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
5/24/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
5/21/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	DRUG Bright Minds Biosciences	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/13/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	DRUG Bright Minds Biosciences	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00
5/10/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMRX Chimerix	$212K	3,778.71	N/A	N/A	$2.17 per share	3.94
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$0.92 per share	N/A
ETNB 89BIO	N/A	N/A	N/A	N/A	$3.34 per share	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMRX Chimerix	-$82.10M	-$0.99	N/A	N/A	N/A	N/A	-50.78%	-44.94%	8/11/2025 (Estimated)
DRUG Bright Minds Biosciences	-$2.06M	-$0.36	N/A	N/A	N/A	N/A	-14.56%	-14.29%	8/13/2025 (Estimated)
ETNB 89BIO	-$367.08M	-$3.38	N/A	N/A	N/A	N/A	-81.44%	-70.17%	8/4/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$0.87	N/A	N/A	N/A	N/A	-16.35%	-15.71%	8/6/2025 (Estimated)

Latest DRUG, GPCR, ETNB, and CMRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q2 2025	DRUG Bright Minds Biosciences	-$0.39	-$0.29	+$0.10	-$0.29	N/A	N/A
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A
5/1/2025	Q1 2025	ETNB 89BIO	-$0.50	-$0.49	+$0.01	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMRX Chimerix	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
ETNB 89BIO	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMRX Chimerix	N/A	6.33	6.33
DRUG Bright Minds Biosciences	N/A	126.01	126.01
ETNB 89BIO	0.06	18.03	18.03
GPCR Structure Therapeutics	N/A	23.29	23.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMRX Chimerix	45.42%
DRUG Bright Minds Biosciences	40.52%
ETNB 89BIO	N/A
GPCR Structure Therapeutics	91.78%

Insider Ownership

Company	Insider Ownership
CMRX Chimerix	13.10%
DRUG Bright Minds Biosciences	42.66%
ETNB 89BIO	2.80%
GPCR Structure Therapeutics	9.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMRX Chimerix	90	93.80 million	78.15 million	Optionable
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable
ETNB 89BIO	40	145.98 million	141.90 million	Optionable
GPCR Structure Therapeutics	136	57.34 million	51.94 million	Optionable

DRUG, GPCR, ETNB, and CMRX Headlines

Recent News About These Companies

Structure Therapeutics (NASDAQ:GPCR) Shares Down 4% - Here's Why

June 26, 2025 | marketbeat.com

Structure Therapeutics' (GPCR) Market Outperform Rating Reaffirmed at JMP Securities

June 25, 2025 | americanbankingnews.com

Jefferies Reiterates a Buy Rating on Structure Therapeutics (GPCR) With a $79 PT

June 24, 2025 | msn.com

Structure Therapeutics' (GPCR) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

June 24, 2025 | americanbankingnews.com

Structure Therapeutics (NASDAQ:GPCR) Shares Up 4.7% - Time to Buy?

June 23, 2025 | marketbeat.com

Cantor Fitzgerald Reaffirms "Overweight" Rating for Structure Therapeutics (NASDAQ:GPCR)

June 23, 2025 | marketbeat.com

JMP Securities Reiterates "Market Outperform" Rating for Structure Therapeutics (NASDAQ:GPCR)

June 23, 2025 | marketbeat.com

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

June 20, 2025 | globenewswire.com

Handelsbanken Fonder AB Buys 215,000 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

June 13, 2025 | marketbeat.com

Structure Therapeutics (NASDAQ:GPCR) Trading Down 4.5% - Time to Sell?

June 12, 2025 | marketbeat.com

Structure Therapeutics (NASDAQ:GPCR) Shares Up 9.4% - Still a Buy?

June 11, 2025 | marketbeat.com

Equities Analysts Set Expectations for GPCR FY2026 Earnings

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Predicts GPCR FY2025 Earnings

June 10, 2025 | marketbeat.com

Structure Therapeutics: Why Aleniglipron's Path To Market Remains Treacherous

June 10, 2025 | seekingalpha.com

Structure Therapeutics Inc. (NASDAQ:GPCR) Given Average Recommendation of "Buy" by Brokerages

June 8, 2025 | marketbeat.com

Bank of America Corp DE Has $1.47 Million Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

June 5, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Makes New $3.09 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

June 3, 2025 | marketbeat.com

Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights

May 9, 2025 | finance.yahoo.com

Citigroup Initiates Coverage of Structure Therapeutics Inc. - Depositary Receipt () (GPCR) with Buy Recommendation

May 3, 2025 | msn.com

Structure draws new Buy at Citi on oral obesity drug pipeline

May 2, 2025 | msn.com

Viking among notable gainers as Pfizer raises deal prospects

April 29, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
By Leo Miller | June 7, 2025
View With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
By Nathan Reiff | June 12, 2025
View Analysts Can't Get Enough of These Little-Known Biopharma Stocks
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
By Leo Miller | June 28, 2025
View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA
By Leo Miller | June 12, 2025
View IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA

DRUG, GPCR, ETNB, and CMRX Company Descriptions

Chimerix NASDAQ:CMRX

$8.54 0.00 (0.00%)

As of 04/21/2025

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Bright Minds Biosciences NASDAQ:DRUG

$26.58 +0.47 (+1.80%)

Closing price 04:00 PM Eastern

Extended Trading

$25.84 -0.73 (-2.77%)

As of 04:46 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

89BIO NASDAQ:ETNB

$9.73 -0.09 (-0.92%)

Closing price 04:00 PM Eastern

Extended Trading

$9.64 -0.09 (-0.91%)

As of 06:39 PM Eastern

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Structure Therapeutics NASDAQ:GPCR

$20.51 -0.23 (-1.11%)

Closing price 04:00 PM Eastern

Extended Trading

$21.10 +0.59 (+2.90%)

As of 05:49 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time